



Introduction

1. About Site-Specific ADC Conjugation



2. Targeting Lysine Residue of AJICAP



AJICAP

AN INNOVATIVE DIRECT CHEMICAL SITE-SELECTIVE CONJUGATION METHOD FOR INTACT NATIVE ANTIBODIES

Wide Antibody Compatibility

- Direct modification of native antibody
- Antibody modifications well-tolerated but not required

Wide Drug-Linker Compatibility

- Hydrophobic Payloads
- Thiol and Azide conjugations

Therapeutic Window Enhancement


- Improvements in PK and efficacy
- Site specific, controlled DAR 2

Straightforward Manufacture


- High productivity
- Short conjugation reaction times
- Ease to manufacture

Overview of 1st Generation AJICAP

3. Concept of AJICAP




4. Synthesis of Site-Specific ADC by AJICAP 1st Generation



Overview of 2nd Generation AJICAP


5. Overview of AJICAP 2nd Generation



Benefit of 2nd Generation AJICAP technology


- Less reaction steps
- Lower aggregation
- Additional conjugation sites (Lys288, etc)
- Azide functionalization enabled

6. Reaction Sequence Comparison of AJICAP 1st and 2nd Generation




Capability of AJICAP

7. Compatibility of AJICAP




9. Synthesis of Various ADCs with 2nd Gen AJICAP Using Modified Reagent



8. Quality Difference Between 1st and 2nd Generation AJICAP-ADCs

DAR by HIC			Aggregation by SEC		
ADCs	1 st gen	2 nd gen	ADCs	1 st gen	2 nd gen
AJICAP-K248Thiol-DM1	1.9	1.9	AJICAP-K248Thiol-DM1	4.7%	0.7%
AJICAP-K248Thiol-MMAF	1.6	1.8	AJICAP-K248Thiol-MMAF	8.9%	0.9%
AJICAP-K248Thiol-PBD	1.3	1.6	AJICAP-K248Thiol-PBD	7.7%	1.8%
Client mAb A + payload X	1.4	1.9	Client mAb A + payload X	40%	1.2%
Client mAb B + payload X	1.6	1.8	Client mAb B + payload X	6.5%	0.4%

10. In Vivo PK, efficacy & Safety Evaluation of AJICAP-ADCs



- Summary**
- AJICAP[®] 2nd generation enables the functionalization of mAbs in a single step without redox chemistry resulting in improved DAR and reduced aggregation.
 - Azide as well as thiol functionality can be introduced through the use of AJICAP[®] 2nd generation technology.
 - AJICAP[®] 2nd generation is capable of introducing payloads in multiple positions on the Fc.
 - AJICAP[®]-ADCs showed enhanced Therapeutic Window and better *in vivo* stability compared to stochastic ADCs.

- References**
- Angew. Chem., Int. Ed. **2019**, 58, 5592–5597.
 - Anal. Chem. **2019**, 91, 12724–12732.
 - Org. Process Res. Dev. **2019**, 23, 2647–2654.
 - ACS Omega **2019**, 4, 20564–20570.
 - Journal of Chromatography B **2020**, 1140, 121981.
 - Antibodies **2020**, 9, 16.
 - J. Am. Soc. Mass. Spectrom. **2020**, 31, 1706–1712.
- Acknowledgements:** Natsuki Shikida, Kazutoshi Takahashi, Kazutaka Shimbo, Ryusuke Hiram, Yumiko Suzuki, Monica Leung.
- Corresponding authors:** Ajinomoto Co., Inc. 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki 210-8681, Japan, Phone: +81-44-244-7163. E-mail: tatsuya_okuzumi@ajinomoto.com